The biopharma world's manufacturing weekly

Endpoints Manufacturing

Manufacturing channel feed

CMO Tal Zaks bids Mod­er­na a sur­prise adieu as biotech projects $18.4B in rev­enue, plots post-Covid ex­pan­sion

5 years ago
People

Dutch biotech In­travacc seeks to bol­ster Nether­lands vac­cine man­u­fac­tur­ing abil­i­ties with new plants

5 years ago

With No­vavax vac­cine deal un­der its belt, SK Bio­science plots out March IPO on the Ko­re­an ex­change

5 years ago

Covid-19 man­u­fac­tur­ing roundup: As­traZeneca strug­gling to make planned vac­cine de­liv­er­ies to EU; J&J out­lines plans to pro­vide 100M dos­es of Covid vac­cine in US as Pfiz­er, Mod­er­na promise speed­i­er de­liv­ery

5 years ago

Bris­tol My­ers scales up cell ther­a­py pro­duc­tion with liso-cel nod in hand and an­oth­er ap­proval maybe on the way

5 years ago
Cell/Gene Tx

Catal­ent un­corks play in plas­mid DNA with buy­out of Bel­gian neigh­bor Del­phi, Mary­land ex­pan­sion launch

5 years ago
Outsourcing

Ore­gon's Cas­cade Chem­istry looks to boost its Amer­i­can-made API pro­duc­tion with $14M in­vest­ment

5 years ago

Covid-19 Man­u­fac­tur­ing Roundup: Ther­mo Fish­er plant ramps up As­traZeneca vac­cine pro­duc­tion; No­vavax ex­pands Ko­re­an man­u­fac­tur­ing pact

5 years ago
Coronavirus

End­points Man­u­fac­tur­ing: 5 Ques­tions with Ho­mol­o­gy Med­i­cines

5 years ago
People

Mallinck­rodt be­comes the lat­est vic­tim of the FDA's pan­dem­ic-re­lat­ed de­lays as it push­es off ap­pli­ca­tion for skin graft

5 years ago
Pharma
FDA+

Is­raeli API mak­er Wave­length buys up ma­jor­i­ty stake in In­di­an firm mak­ing drug start­ing ma­te­ri­als and in­ter­me­di­ates

5 years ago
Outsourcing

End­points Man­u­fac­tur­ing: Charles Riv­er makes a splash for cell and gene ther­a­py spe­cial­ist; 5 ques­tions with Ho­mol­o­gy Med­i­cines

5 years ago

Cen­tu­ry Ther­a­peu­tics boosts iP­SC man­u­fac­tur­ing space in New Jer­sey as part of com­pa­ny wide ex­pan­sion

5 years ago
Cell/Gene Tx

Charles Riv­er Lab­o­ra­to­ries snaps up Cog­nate for a cool $875M, looks to ex­pand cell and gene ther­a­py CD­MO foothold

5 years ago
Deals

Hous­ton's Avance Bio­sciences an­nounces an­oth­er ex­pan­sion, this time fo­cused on cell-based as­says

5 years ago

FDA slaps Flori­da's Al­lay Phar­ma­ceu­ti­cals with warn­ing let­ter over vague re­spons­es to drug po­ten­cy is­sues

5 years ago
FDA+

Vi­gene Bio­sciences goes big on Mary­land vi­ral vec­tor ex­pan­sion as it rides high on Al­tim­mune vac­cine deal

5 years ago

End­points Man­u­fac­tur­ing: Lon­za drops in­gre­di­ents biz in $4.7B sale; Touch­light's 'dog­gy­boneD­NA' looks to rewrite rules of ther­a­peu­tic DNA

5 years ago

Ger­many's Rentschler looks to build UK foot­print with five-year in­vest­ment in cell and gene ther­a­pies

5 years ago
Deals

Quo­tient, buoyed by Covid-19 work, buys Ar­ci­no­va in ef­fort to build end-to-end CD­MO brand

5 years ago
Deals

Fre­se­nius Kabi pays $50 mil­lion to set­tle crim­i­nal charges

5 years ago
FDA+

In­di­a's TCG launch­es new CD­MO arm state­side to meet the call for 'Amer­i­can-made' pan­dem­ic drugs

5 years ago

As­traZeneca looks to re­bound from pro­duc­tion de­lays for its Covid-19 vac­cine with new fill-fin­ish deal

5 years ago
Outsourcing
Coronavirus

Lon­za of­floads spe­cial­ty in­gre­di­ents unit in $4.7B sale to Bain Cap­i­tal, Cin­ven in con­sol­i­da­tion around bio­phar­ma

5 years ago
Outsourcing
First page Previous page 757677787980 Next page Last page
A service from the Financial Times